Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
1.
Clin Immunol ; : 108749, 2021 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-33945872

RESUMO

Anti-mitochondrial antibodies (AMA), directed against the E2 subunits of the 2-oxo acid dehydrogenase complexes, are markers of Primary Biliary Cholangitis (PBC), a chronic autoimmune liver disease. However, the clinical significance of subunits-specific AMA type PDC-E2 -E2 subunit of the pyruvate dehydrogenase complex-, BCOADC-E2 -E2 subunit of the branched-chain 2-oxo acid dehydrogenase complex-, OGDC-E2 -E2 subunit of the 2-oxo-glutarate dehydrogenase complex- and nPDC -native pyruvate dehydrogenase complex (M2-AMA) . Is not well known, and not all AMA specificities are associated with PBC. The aim of the study was to show the usefulness of the number and combination of subunits-specific AMA positive for the diagnosis of PBC. We detected AMA by indirect immunofluorescence (IIF-AMA) and M2-AMA by dot-blot. We studied the relationship of AMA with some clinical and laboratory variables in 307 patients (37% PBC) with positive dot-blot for M2-AMA. In PBC patients, we detected different E2 subunits of the 2-oxo acid dehydrogenase complexes antibodies (M2-AMA): 82.9% were specific for nPDC, 64.5% for PDC-E2, 44.4% for BCOADC-E2, and 9.6% for OGDC-E2. IIF and dot-blot tests achieved a Area Under the Receiver Operating Characteristic Curve (ROC AUC) of 0.674 (1: 320 cut-off titer, Sensibility (Se) 64.7%, Specificity (Sp) 63.4%) and 0.663 (three specificities M2-AMA, Se 43%, Sp 81.2%), respectively. The detection of different E2 subunits of the 2-oxo acid dehydrogenase complexes antibodies (M2-AMA) by dot-blot showed different ROC AUC: anti-PDC-E2 showed an AUC of 0.610, a Se of 43.7%, and a Sp of 76.4%. Finally, the combined detection of nPDC/BCOADC-E2/PDC-E2 reached an AUC of 0.6095, a Se of 59.6%, and a Sp of 70.2%.The identification of two M2-AMA specificities through dot-blot increased PBC odds ratio (OR) by 2.05 (p:0.031), as compared to the identification of one specificity. Moreover, the identification of three and four specificities increased OR by 4.63 (p:0.000) and by 21.53 (p:0.006), respectively. nPDC/OGDC-E2/PDC-E2 and nPDC/OGDC-E2/BCOADC-E2/PDC-E2 combinations increased PBC OR by 10.04 (p:0.034), as compared to any other combination. 1:320 and 1:640 IIF-AMA increased PBC OR by 4.93 (p:0.009) and 7.67 (p:0.001), respectively, as compared to IIF-AMA titers equal to or less than 1:160. M2-AMA dot-blot was less sensitive but more specific than IIF-AMA, with similar predictive capacity for PBC. Increased numbers of M2-AMA specificities clearly increased the risk of PBC. Some combinations were strongly related to PBC (nPDC/BCOADC-E2/PDC-E2), but others were not (one single M2-AMA, and nPDC plus PDC-E2). M2-AMA dot-blot was less sensitive but more specific than IIF-AMA, with similar predictive capacity for PBC. Increased numbers of M2-AMA specificities clearly increased the risk of PBC, being some combinations, such as nPDC/BCOADC-E2/PDC-E2, more related to PBC than others. Finally, the determination of the number of M2-AMA specificities was more useful than the particular subunit target for PBC diagnosis. In conclusion, the study of the number of M2-AMA specificities by dot-blot should definitely be considered for PBC diagnosis.

2.
Ther Drug Monit ; 42(1): 102-110, 2020 02.
Artigo em Inglês | MEDLINE | ID: mdl-31283556

RESUMO

BACKGROUND AND AIMS: Treating patients based on a treat-to-trough approach has been shown to be a cost-effective strategy for inflammatory bowel disease (IBD) patients who have become unresponsive to infliximab (IFX). However, the documented evidence for this is limited, and some controversy remains regarding the use of routine proactive therapeutic drug monitoring (TDM). To support routine TDM of IFX and regimen optimization in IBD patients, more in-depth knowledge of the covariates that affect the pharmacokinetic (PK) variability of IFX is needed. The aim of this study was to identify the characteristics of the patient, disease, and treatments that influence IFX PK and exposure in our cohort of IBD patients using a repeated-measures design. METHODS: We performed a prospective observational study of adult IBD patients who received IFX between July 2013 and March 2017. We obtained repeated IFX trough concentration (Cmin) measurements and implemented a previously described population pharmacokinetic model to estimate individual clearance (CL). From the individual primary parameters, the area under the curve (AUC), half-life (t1/2), and central elimination rate constant (K10) were estimated. We performed a repeated-measures analysis to evaluate whether patient characteristics, disease status, concomitant immunosuppressive therapy, and immunogenicity are associated with IFX Cmin and PK parameters. RESULTS: We collected 429 Cmin measurements from 112 patients. The median of the Cmin values was 3.62 mg/L (1.47-6.02). Antibodies to IFX (ATI) were detected in 14 patients. The predicted median AUC was 28,421 mg/h/L (22,336-36,903). The median individual predicted CL, K10, and t1/2 values were 4.77 mL/kg/day (3.88-5.90), 0.09 days (0.08-0.12), and 12.22 days (9.49-14.87), respectively. IFX Cmin, AUC, CL, and K10 were significantly influenced by ATI and serum albumin concentrations. Moreover, body weight was significantly associated with AUC, CL, and K10. Patients receiving concurrent immunosuppressive therapy had higher Cmin and AUC values and lower CL and K10 values than those treated with IFX monotherapy. We also observed high intrapatient variability in Cmin values during the study period. CONCLUSIONS: In this repeated-measures study in a population of IBD patients, we observed significant associations between ATI, serum albumin concentration, concomitant immunosuppressive therapy, body weight and gender, and IFX Cmin, and CL. The high PK variability observed in this study supports the need for proactive TDM to optimize the use of IFX as early as possible in IBD patients.


Assuntos
Monitoramento de Medicamentos/métodos , Fármacos Gastrointestinais/farmacocinética , Fármacos Gastrointestinais/uso terapêutico , Doenças Inflamatórias Intestinais/tratamento farmacológico , Infliximab/farmacocinética , Infliximab/uso terapêutico , Adulto , Área Sob a Curva , Quimioterapia Combinada , Feminino , Fármacos Gastrointestinais/administração & dosagem , Fármacos Gastrointestinais/imunologia , Meia-Vida , Humanos , Imunossupressores/uso terapêutico , Infliximab/administração & dosagem , Infliximab/imunologia , Masculino , Pessoa de Meia-Idade , Modelos Biológicos , Estudos Prospectivos , Albumina Sérica
3.
Ther Drug Monit ; 40(1): 120-129, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-29200097

RESUMO

BACKGROUND: Infliximab (IFX) trough levels vary markedly between patients with inflammatory bowel disease (IBD), which is important for clinical response. The aim of this study was to evaluate the performance of previously developed population pharmacokinetic models in patients with IBD for dose individualization for Crohn disease (CD) and ulcerative colitis in our clinical setting. METHODS: The authors collected 370 trough levels prospectively from 100 adult patients with IBD who were undergoing IFX treatment between July 2013 and August 2016. The external evaluation included prediction- and simulation-based diagnostics [prediction-corrected visual predictive check, prediction- and variability-corrected visual predictive check, and normalized prediction distribution error tests]. RESULTS: In prediction-based diagnostics, the authors observed a nonsignificant overall mean relative bias of -6.87% and an acceptable imprecision of 8.45%. Approximately 100% of the prediction error was within ±30%, indicating satisfactory predictability. Simulation-based diagnostics indicated model misspecification; thus, the model may not be appropriate for simulation-based applications. CONCLUSIONS: While simulation-based diagnostics provided unsatisfactory results, the prediction-based diagnostics demonstrate that the population pharmacokinetic model developed by Fasanmade et al for CD can be used to predict and design individualized IFX dose regimens that meet the individual needs of patients with CD and ulcerative colitis.


Assuntos
Infliximab/farmacocinética , Modelos Biológicos , Anticorpos Monoclonais/sangue , Anticorpos Monoclonais/farmacocinética , Simulação por Computador , Feminino , Humanos , Doenças Inflamatórias Intestinais/sangue , Infliximab/sangue , Masculino
4.
Front Immunol ; 13: 895209, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35572562

RESUMO

Introduction: SARS-CoV-2 vaccines' effectiveness is not yet clearly known in immunocompromised patients. This study aims to assess the humoral and cellular specific immune response to SARS-CoV-2 vaccines and the predictors of poor response in patients with common variable immunodeficiency (CVID) phenotype and in patients treated with B-cell depletion therapies (BCDT), as well as the safety of these vaccines. Methods: From March to September 2021, we performed a prospective study of all adult patients who would receive the SARS-CoV-2 vaccination and were previously diagnosed with (i) a CVID syndrome (CVID phenotype group; n=28) or (ii) multiple sclerosis (MS) treated with B-cell depleting therapies three to six months before vaccination (BCD group; n=24). Participants with prior SARS-CoV-2 infection; or prior SARS-CoV-2 vaccine administration; or use of any immunosuppressant (except BCDT in MS group) were excluded. A group of subjects without any medical condition that confers immunosuppression and who met all study criteria was also assessed (control group; n=14). A chemiluminescence immunoassay was used to determine pre- and post-SARS-CoV-2 vaccine anti-S IgG antibodies. T-cell specific response was assessed by analysis of pre- and post-SARS-CoV-2 vaccination blood samples with an interferon-gamma release assay. The baseline blood sample also included several biochemical, haematological and immunological analyses. Results: SARS-CoV-2 vaccines are safe in immunocompromised patients, although their effectiveness was lower than in healthy individuals. CVID phenotype patients showed impaired humoral (29%) and cellular (29%) response, while BCD patients fundamentally presented humoral failure (54%). Low IgA values, low CD19+ peripheral B cells, low switched memory B cells, and a low CD4+/CD8+ ratio were predictors of inadequate specific antibody response in CVID phenotype patients. No factor was found to predict poor cellular response in CVID phenotype patients, nor a defective humoral or cellular response in BCD patients. Conclusion: The effectiveness of SARS-CoV-2 vaccines in CVID phenotype and BCD patients is lower than in healthy individuals. Knowledge of predictive factors of humoral and cellular response failure in immunocompromised patients could be very useful in clinical practice, and thus, studies in this regard are clearly needed.


Assuntos
COVID-19 , Imunodeficiência de Variável Comum , Anticorpos Antivirais , Vacinas contra COVID-19 , Imunodeficiência de Variável Comum/terapia , Humanos , Imunidade Celular , Fenótipo , Estudos Prospectivos , SARS-CoV-2
5.
Front Med (Lausanne) ; 8: 691712, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34195214

RESUMO

Introduction: Severe lung injury is triggered by both the SARS-CoV-2 infection and the subsequent host-immune response in some COVID-19 patients. Methods: We conducted a randomized, single-center, open-label, phase II trial with the aim to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus plus standard of care (SoC) vs. SoC alone, in hospitalized patients with severe COVID-19. The primary outcome was time to clinical stability within 56 days after randomization. Results: From April 1 to May 2, 2020, 55 patients were prospectively included for subsequent randomization; 27 were assigned to the experimental group and 28 to the control group. The experimental treatment was not associated with a difference in time to clinical stability (hazard ratio 0.73 [95% CI 0.39-1.37]) nor most secondary outcomes. Median methylprednisolone cumulative doses were significantly lower (360 mg [IQR 360-842] vs. 870 mg [IQR 364-1451]; p = 0.007), and administered for a shorter time (median of 4.00 days [3.00-17.5] vs. 18.5 days [3.00-53.2]; p = 0.011) in the experimental group than in the control group. Although not statistically significant, those receiving the experimental therapy showed a numerically lower all-cause mortality than those receiving SoC, especially at day 10 [2 (7.41%) vs. 5 (17.9%); OR 0.39 (95% CI 0.05-2.1); p = 0.282]. The total number of non-serious adverse events was 42 in each the two groups. Those receiving experimental treatment had a numerically higher rate of non-serious infectious adverse events [16 (38%) vs. 10 (24%)] and serious infectious adverse events [7 (35%) vs. 3 (23%)] than those receiving SoC. Conclusions: The combined use of methylprednisolone pulses plus tacrolimus, in addition to the SoC, did not significantly improve the time to clinical stability or other secondary outcomes compared with the SoC alone in severe COVID-19. Although not statistically significant, patients receiving the experimental therapy had numerically lower all-cause mortality than those receiving SoC, supporting recent non-randomized studies with calcineurin inhibitors. It is noteworthy that the present trial had a limited sample size and several other limitations. Therefore, further RCTs should be done to assess the efficacy and safety of tacrolimus to tackle the inflammatory stages of COVID-19. Clinical Trial Registration: Identifier [NCT04341038/EudraCT: 2020-001445-39].

6.
Neurobiol Dis ; 38(1): 1-7, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20044003

RESUMO

Neuronal cell death by apoptosis is a mechanism involved in Parkinson's disease and indirect signs of apoptosis have been found in brain neurons and blood lymphocytes. The present study was aimed to directly assess the presence of enhanced apoptosis in lymphocytes from 89 idiopathic Parkinson's disease patients, 33 untreated and 56 treated, compared with 33 healthy individuals. The study of both spontaneous and activation-induced apoptosis of T-lymphocyte subsets by annexin-V binding and flow cytometry showed that Parkinson patients increased the expression of Fas in circulating CD4(+) T cells, mainly "naive," that correlated with the decrease of these cells in blood. Spontaneous and activation-induced apoptosis of CD4(+) T-cell subsets were also significantly increased. Thus, in Parkinson patients, peripheral blood CD4(+) T cells have an increased susceptibility to apoptosis with Fas involvement. This fact explains the decrease in the number of CD4(+) T-cell subsets observed in Parkinson and could be related to the neurodegenerative process.


Assuntos
Apoptose/imunologia , Linfócitos T CD4-Positivos/imunologia , Degeneração Neural/imunologia , Degeneração Neural/fisiopatologia , Doença de Parkinson/imunologia , Doença de Parkinson/fisiopatologia , Idoso , Anexina A5/metabolismo , Ligação Competitiva , Biomarcadores/metabolismo , Linfócitos T CD4-Positivos/metabolismo , Células Cultivadas , Estudos de Coortes , Feminino , Citometria de Fluxo , Humanos , Ativação Linfocitária/fisiologia , Masculino , Pessoa de Meia-Idade , Degeneração Neural/metabolismo , Neurônios/imunologia , Neurônios/metabolismo , Doença de Parkinson/metabolismo , Receptor fas/análise , Receptor fas/metabolismo
7.
Sci Rep ; 7(1): 11902, 2017 09 19.
Artigo em Inglês | MEDLINE | ID: mdl-28928425

RESUMO

The cornification of keratinocytes on the surface of skin and oral epithelia is associated with the degradation of nuclear DNA. The endonuclease DNase1L2 and the exonuclease Trex2 are expressed specifically in cornifying keratinocytes. Deletion of DNase1L2 causes retention of nuclear DNA in the tongue epithelium but not in the skin. Here we report that lack of Trex2 results in the accumulation of DNA fragments in the cytoplasm of cornifying lingual keratinocytes and co-deletion of DNase1L2 and Trex2 causes massive accumulation of DNA fragments throughout the cornified layers of the tongue epithelium. By contrast, cornification-associated DNA breakdown was not compromised in the epidermis. Aberrant retention of DNA in the tongue epithelium was associated neither with enhanced expression of DNA-driven response genes, such as Ifnb, Irf7 and Cxcl10, nor with inflammation. Of note, the expression of Tlr9, Aim2 and Tmem173, key DNA sensor genes, was markedly lower in keratinocytes and keratinocyte-built tissues than in macrophages and immune tissues, and DNA-driven response genes were not induced by introduction of DNA in keratinocytes. Altogether, our results indicate that DNase1L2 and Trex2 cooperate in the breakdown and degradation of DNA during cornification of lingual keratinocytes and aberrant DNA retention is tolerated in the oral epithelium.


Assuntos
Fragmentação do DNA , DNA/genética , Desoxirribonucleases/genética , Exodesoxirribonucleases/genética , Deleção de Genes , Queratinócitos/metabolismo , Animais , Linhagem Celular , Células Cultivadas , Humanos , Camundongos Endogâmicos C57BL
8.
Autoimmunity ; 49(2): 102-8, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26699543

RESUMO

The "rods and rings" (RR) antinuclear antibody (ANA) pattern is believed to be restricted to hepatitis C virus (HCV) infection and related to the treatment. This is a 4-year retrospective study of all patients with RR pattern from the 20,000 serum samples received at the Hospital Universitari de Bellvitge for ANA testing. Two control groups with HCV patients without RR pattern: ANA-positive (n = 74) and ANA negative (n = 75) were included. Eighty-seven patients had samples with the RR pattern. Seventy-three were infected with HCV (prevalence of 15% in the HCV population). The RR pattern could not be related to ribavirin treatment, clinical status, biochemistry data, hepatic fibrosis, IL28B genotype, HCV genotype or the presence of autoantibodies related with autoimmune hepatitis. As 14 cases presented other diseases, mainly of autoimmune origin, the presence of RR antibodies may also be explained by alterations in immune regulation caused by autoimmunity or HCV in a particular genetic background.


Assuntos
Anticorpos Antinucleares/imunologia , Hepacivirus , Hepatite C/imunologia , Hepatite C/virologia , Adulto , Idoso , Anticorpos Antinucleares/sangue , Antivirais/uso terapêutico , Estudos de Casos e Controles , Feminino , Genótipo , Hepacivirus/genética , Hepatite C/tratamento farmacológico , Hepatite C/genética , Humanos , Interferons , Interleucinas/genética , Cirrose Hepática/etiologia , Cirrose Hepática/patologia , Testes de Função Hepática , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento
9.
Am J Kidney Dis ; 39(5): E21, 2002 May.
Artigo em Inglês | MEDLINE | ID: mdl-11979333

RESUMO

Two months after surgical resection of a bronchogenic carcinoma, a 69-year-old patient presented with Schönlein-Henoch purpura with kidney involvement followed by pulmonary hemorrhage. The presence of an IgA linear pattern on the kidney biopsy specimen and circulating anti-glomerular basement membrane (GBM) IgA antibodies led to the diagnosis of Goodpasture syndrome, which implies the possibility that the well-known pulmonary involvement during the course of Schönlein-Henoch purpura could be caused by Goodpasture syndrome in certain cases. In cases of glomerulonephropathy with lung involvement, clinicians should not limit their investigations to anti-GBM IgG.


Assuntos
Doença Antimembrana Basal Glomerular/etiologia , Vasculite por IgA/complicações , Idoso , Doença Antimembrana Basal Glomerular/sangue , Doença Antimembrana Basal Glomerular/tratamento farmacológico , Esquema de Medicação , Evolução Fatal , Humanos , Vasculite por IgA/sangue , Vasculite por IgA/tratamento farmacológico , Imunoglobulina A/sangue , Imunoglobulinas Intravenosas/administração & dosagem , Imunoglobulinas Intravenosas/uso terapêutico , Infusões Intravenosas , Prednisona/administração & dosagem , Prednisona/uso terapêutico
10.
APMIS ; 111(3): 371-81, 2003 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-12752216

RESUMO

PAF antagonists have been used in xenotransplantation to alleviate the pathogenesis of hyperacute rejection. This study evaluated the ability of the PAF antagonist UR-12670 to improve graft function in late xenograft rejection (LXR) in an orthotopic liver xenotransplantation model, and the involvement of PAF (platelet activating factor) in this type of rejection. The recipients of a hamster xenograft received standard immunosuppression (tacrolimus 0.2 mg/kg/30 days, MMF 25 mg/kg/8 days). Study groups: group A, without UR-12670, group B, UR-12670 (20 mg/kg/8 d) and group C, continuous administration of UR-12670 (20 mg/kg/d). Serum levels of xenoantibodies were evaluated by flow cytometry and tissue deposits by immunofluorescence. Immunoblot and indirect immunofluorescence assessed specificity of xenoantibodies. Conventional histology was performed. Continuous administration of UR-12670 improved the histological pattern of liver xenografts, especially necrosis, loss of hepatocytes, hemorrhage, sinusoidal congestion and lymphocyte infiltration. There was not a shift in specificity of xenoantibodies at different times posttransplantation, as demonstrated by immunoblotting and indirect immunofluorescence. UR-12670 administration had a beneficial effect on graft function and considerably improved the histopathological pattern, but it failed to induce tolerance after withdrawal of immunosuppression. UR-12670 had an immunomodulatory effect on cellular response but not on antibody production. There was not a change in the specificity of xenoantibodies produced at LXR compared with pretransplant antibodies.


Assuntos
Sobrevivência de Enxerto/efeitos dos fármacos , Imidazóis/farmacologia , Transplante de Fígado/patologia , Fator de Ativação de Plaquetas/antagonistas & inibidores , Piridinas/farmacologia , Transplante Heterólogo/patologia , Alanina Transaminase/sangue , Animais , Anticorpos Heterófilos/sangue , Especificidade de Anticorpos , Aspartato Aminotransferases/sangue , Western Blotting , Cricetinae , Técnica Indireta de Fluorescência para Anticorpo , Sobrevivência de Enxerto/imunologia , Imunoglobulina G/imunologia , Imunoglobulina G/metabolismo , Imunoglobulina M/imunologia , Imunoglobulina M/metabolismo , Fígado/patologia , Fígado/fisiologia , Transplante de Fígado/imunologia , Masculino , Mesocricetus , Fator de Ativação de Plaquetas/farmacologia , Ratos , Ratos Endogâmicos Lew , Albumina Sérica/metabolismo , Transplante Heterólogo/imunologia
11.
Neurosci Lett ; 363(1): 14-7, 2004 Jun 03.
Artigo em Inglês | MEDLINE | ID: mdl-15157986

RESUMO

We analyzed the prognostic value of Tau protein, a marker of axonal damage, detected in the cerebrospinal fluid (CSF) of patients with relapsing-remitting multiple sclerosis (RRMS). We sampled the CSF from 32 patients with probable or definite RRMS, having had the disease for less than 5 years. We studied the relationship between Tau protein concentration in the CSF (CSF-TAU) and disability, time to next relapse and time to experience a one point increase on the Expanded Disability Status Scale (EDSS). CSF-TAU was correlated with the Progression Index at the end of follow-up. Patients with higher CSF-TAU experienced a more rapid one point increase in the EDSS. CSF-TAU was the only independent variable to predict the time to next relapse. CSF-TAU, as a marker of axonal loss, may help us to predict short-term outcome in patients with early RRMS.


Assuntos
Esclerose Múltipla Recidivante-Remitente/líquido cefalorraquidiano , Proteínas tau/líquido cefalorraquidiano , Adulto , Biomarcadores/líquido cefalorraquidiano , Distribuição de Qui-Quadrado , Progressão da Doença , Ensaio de Imunoadsorção Enzimática/métodos , Feminino , Seguimentos , Humanos , Masculino , Esclerose Múltipla Recidivante-Remitente/diagnóstico , Prognóstico , Valores de Referência , Estudos Retrospectivos , Índice de Gravidade de Doença , Punção Espinal/métodos , Estatísticas não Paramétricas , Fatores de Tempo
12.
Transplantation ; 92(5): 536-42, 2011 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-21849930

RESUMO

BACKGROUND: Detection of markers predicting allograft rejection is important for risk assessment before kidney transplantation, as well as to minimize posttransplantation immunosuppression. METHODS: We studied the expression of CD25, HLA-DR, CD134, CD62L, and CD44 by flow cytometry in CD4, CD8, and CD3 cells, from pretransplant blood samples from 91 transplanted patients accounting for 16 episodes of acute renal rejection in the first month after transplantation. RESULTS: None of the activation markers showed a significant association to acute rejection. Early rejectors showed less pretransplant CD3CD25 cells than nonrejectors (0.79%±0.50% vs. 1.51%±0.79% of CD3 cells; P=0.001) and a lower CD3CD25/CD3HLA-DR ratio (0.043±0.034 vs. 0.111±0.079; P<0.00001). When levels of CD25 cells fell below 0.7% of CD3 cells, the odds ratio of suffering an episode of acute rejection was 105 fold (95% confidence interval: 11.41-966.43, P<0.0001), with a sensitivity (true-positive results) of 0.63 and a specificity (true-negative results) of 0.98 for predicting the risk of acute rejection. Furthermore, when the CD3CD25/CD3HLA-DR ratio fell below 0.04, the odds ratio of suffering an episode of acute rejection was 7.71 fold (95% confidence interval: 2.29-25.97, P=0.001), with a sensitivity of 0.56 and a specificity of 0.86 for predicting risk of acute rejection. CONCLUSIONS: Our results suggest that low pretransplant levels of CD3CD25 cells or a low CD3CD25/CD3HLA-DR ratio could identify those patients with an increased risk of early acute allograft rejection. If these data can be independently confirmed, pretransplant CD3CD25 cells and the CD3CD25/CD3HLA-DR ratio might provide additional information for risk assessment before kidney transplantation.


Assuntos
Rejeição de Enxerto/etiologia , Rejeição de Enxerto/imunologia , Transplante de Rim/efeitos adversos , Transplante de Rim/imunologia , Subpopulações de Linfócitos T/imunologia , Doença Aguda , Adulto , Idoso , Complexo CD3/metabolismo , Linfócitos T CD4-Positivos/imunologia , Feminino , Antígenos HLA-DR/metabolismo , Humanos , Subunidade alfa de Receptor de Interleucina-2/metabolismo , Ativação Linfocitária , Contagem de Linfócitos , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Linfócitos T Reguladores/imunologia
13.
Semin Arthritis Rheum ; 38(2): 101-9, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18221987

RESUMO

OBJECTIVE: The diagnosis of rheumatoid arthritis (RA) is sometimes difficult to establish early in the disease process, particularly in the absence of its classic hallmarks. Our aim was to compare the practical usefulness of magnetic resonance imaging (MRI) of the hand versus anticyclic citrullinated peptide (anti-CCP) antibody testing to confirm the diagnosis of clinically suspected RA in the absence of rheumatoid factor (RF) and radiographic erosions. METHODS: We prospectively included patients with early inflammatory arthritis and strong clinical suspicion of RA, in whom initial complementary tests (RF and radiographs of hands, wrists, and feet) did not provide unequivocal confirmation of the diagnosis. In all patients, anti-CCP antibodies were assessed and contrast-enhanced MRI of the most affected hand was performed according to a specifically designed protocol. The MRI criterion for the diagnosis of RA was either the presence of synovitis with bone erosions or bone marrow edema, which is currently considered to be a forerunner of erosions. RESULTS: In the 40 patients (28 women), the mean age at diagnosis was 54 +/- 6 years and the median duration of symptoms was 4 +/- 2.6 months (range 1.5 to 12). Final diagnoses at 1-year follow-up were RA in 31 patients, undifferentiated arthritis in 7 (5 self-limiting), and psoriatic arthropathy (PsA) and antisynthetase syndrome in 1 patient each. Anti-CCP antibodies were positive only in 7 patients, all of whom were finally diagnosed with RA. The prevalence of anti-CCP positivity in our series of seronegative RA patients was thus 23% (7/31); in these patients the anti-CCP antibodies had a specificity of 100% (95% CI: 71.7 to 100) and sensitivity of 23% (95% CI: 9.6 to 41.1). Use of the MRI criterion led to the correct diagnosis in 100% of patients with RA and to false-positive results (1 with PsA and 1 with antisynthetase syndrome). The MRI criterion had a specificity of 78% (95% CI: 40.0 to 97.2) and sensitivity of 100% (95% CI: 90.8 to 100) for identification of seronegative RA. CONCLUSION: Although the tests are not mutually exclusive, in our experience MRI is more helpful than anti-CCP antibody determination in confirming the diagnosis of clinically suspected early RA in patients in whom the diagnosis cannot be confirmed using conventional methods.


Assuntos
Anticorpos/uso terapêutico , Artrite Reumatoide/diagnóstico , Artrite Reumatoide/imunologia , Imageamento por Ressonância Magnética , Peptídeos Cíclicos/imunologia , Artrite Reumatoide/sangue , Artrite Reumatoide/diagnóstico por imagem , Feminino , Mãos , Humanos , Masculino , Pessoa de Meia-Idade , Radiografia , Fator Reumatoide/sangue , Sensibilidade e Especificidade
14.
J Immunol ; 179(7): 4901-9, 2007 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-17878390

RESUMO

Exploring new immunosuppressive strategies inducing donor-specific hyporesponsiveness is an important challenge in transplantation. For this purpose, a careful immune monitoring and graft histology assessment is mandatory. Here, we report the results of a pilot study conducted in twenty renal transplant recipients, analyzing the immunomodulatory effects of a protocol based on induction therapy with rabbit anti-thymocyte globulin low doses, sirolimus, and mofetil mycophenolate. Evolution of donor-specific cellular and humoral alloimmune response, peripheral blood lymphocyte subsets and apoptosis was evaluated. Six-month protocol biopsies were performed to assess histological lesions and presence of FOXP3+ regulatory T cells (Tregs) in interstitial infiltrates. After transplantation, there was an early and transient apoptotic effect, mainly within the CD8+ HLADR+ T cells, combined with a sustained enhancement of CD4+ CD25(+high) lymphocytes in peripheral blood. The incidence of acute rejection was 35%, all steroid sensitive. Importantly, only pretransplant donor-specific cellular alloreactivity could discriminate patients at risk to develop acute rejection. Two thirds of the patients became donor-specific hyporesponders at 6 and 24 mo, and the achievement of this immunologic state was not abrogated by prior acute rejection episodes. Remarkably, donor-specific hyporesponders had the better renal function and less chronic renal damage. Donor-specific hyporesponsiveness was inhibited by depleting CD4+ CD25(+high) T cells, which showed donor-Ag specificity. FOXP3+ CD4+ CD25(+high) Tregs both in peripheral blood and in renal infiltrates were higher in donor-specific hyporesponders than in nonhyporesponders, suggesting that the recruitment of Tregs in the allograft plays an important role for renal acceptance. In conclusion, reaching donor-specific hyporesponsiveness is feasible after renal transplantation and associated with Treg recruitment in the graft.


Assuntos
Fatores de Transcrição Forkhead/imunologia , Fatores de Transcrição Forkhead/metabolismo , Transplante de Rim/imunologia , Linfócitos T Reguladores/imunologia , Linfócitos T Reguladores/metabolismo , Animais , Apoptose , Biópsia , Feminino , Seguimentos , Rejeição de Enxerto/imunologia , Rejeição de Enxerto/patologia , Rejeição de Enxerto/prevenção & controle , Humanos , Imunossupressores/farmacologia , Testes de Função Renal , Transplante de Rim/efeitos adversos , Masculino , Pessoa de Meia-Idade , Linfócitos T Reguladores/citologia , Transplante Homólogo/imunologia
16.
Inmunología (1987) ; Inmunología (1987);28(2): 74-78, abr.-jun. 2009. ilus, tab
Artigo em Inglês | IBECS (Espanha) | ID: ibc-108248

RESUMO

Despite their clinical utility and the importance that laboratory testshave in APS diagnosis, probably the most important drawback of suchtests is the elevated intra- and inter-laboratory variation. The aim of thepresent work was to assess the multilaboratory performance of aCL (..) (AU)


A pesar de la indudable utilidad clínica y de la importancia de laspruebas de laboratorio en el diagnóstico del síndrome antifosfolípido(APS), probablemente el mayor defecto de dichas pruebas es su elevadavariabilidad intra- e inter-laboratorio. El objetivo del presente trabajo fueevaluar el comportamiento de los ensayos (..) (AU)


Assuntos
Humanos , Anticorpos Anticardiolipina/imunologia , beta 2-Glicoproteína I/antagonistas & inibidores , Autoimunidade/imunologia , Síndrome Antifosfolipídica/imunologia , Anticorpos Antifosfolipídeos/imunologia , Cursos , Inibidor de Coagulação do Lúpus/imunologia
17.
Villegas Martín, Eduardo; Julià Benique, M Rosa; Martínez García, Pedro; Carrasco Sayalero, Ángela; Sánchez Ibarrola, Alfonso; Ocaña Pérez, Esther; Marcaida Benito, Goitzane; Rodríguez Delgado, Juana; Martínez Becerra, María José; Laporta Martín, Paz; Fernández Pereira, Luis; Aránzazu Pacho de Lucas, María; Jiménez Garófano, Carmen; Vinyas Gomis, Odette; Garcia, Mila; Dieli Crimi, Romina; Eiras Martínez, Pablo; Bas, Jordi; Muñoz Calleja, Cecilia; García Marcos, Margarita; Calleja Antolín, Sara; López Hoyos, Marcos; Espárrago Rodilla, Manuel; Gelpí Sabater, Carmen; Prada Iñurrategui, Álvaro; Raquel Sáez, J; Ontañón Rodríguez, Jesús; Alcalá Peña , M Inmaculada; Vargas Pérez, M Luisa; Jurado Roger, Aurora; Vlagea, Alexandru; Pastor Barellas, Rosa María; Roy Ariño, Garbiñe; Jiménez Jiménez, Juana; Muñoz Vico, Francisco Javier; Martínez Cáceres, Eva M; Pascual-Salcedo Pascual, Dora; Álvarez Doforno, Rita; Serrano, Antonio; Paz Artal, Estela; Torio Gómez, Silvina; Cid Fernández, José Javier; Mozo Avellaned, Lourdes; Barrios del Pino, Yvelise; Alarcón Torres, Inmaculada; Rodríguez Mahou, Margarita; Montes Ares, Olga; Torio Ruiz, Alberto; Almeida González, Delia; Plaza López , Aresio; Rodríguez Hernández, Carmen; Aparicio Hernández, María Belén; Sánchez , Ana Marín; García Pacheco, José Marcos; Montes Cano, Marco Antonio; González Rodríguez, Concepción; Jaimez Gámiz, Laura; Rodríguez Gutiérrez, Juan Francisco; Alsina Donadeu, Montserrat; Pujalte Mora, Francisco; Amengual Guedan, María José.
Inmunología (1987) ; Inmunología (1987);32(4): 148-156, oct.-dic. 2013. ilus, tab
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-117493
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA